Court Rejects Mylan’s Rehearing Request in Two Patent Suits

The second highest court in the land rejected Mylan’s requested rehearing in two patent lawsuits, leaving the company with few options for avoiding the cases.

The U.S. Court of Appeals for the Federal Circuit did not give a reason for its denial of Mylan’s petition for a rehearing before the entire circuit, letting stand a three-judge panel’s ruling in March that the company must face suits filed in Delaware by AstraZeneca and Acorda Therapeutics.

The suits contend that Mylan’s filing of ANDAs for generic versions of AstraZeneca’s diabetes drugs Onglyza and Kombiglyze, as well as Acorda’s multiple sclerosis drug Ampyra threatened their patents.